Neuroretinal Rim Area Change in Glaucoma Patients with Visual Field Progression Endpoints and Intraocular Pressure Reduction. the Canadian Glaucoma Study: 4

Canadian Glaucoma Study Group

doi:10.1016/j.ajo.2015.11.031

Neuroretinal Rim Area Change in Glaucoma Patients with Visual Field Progression Endpoints and Intraocular Pressure Reduction. the Canadian Glaucoma Study: 4

Canadian Glaucoma Study Group

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

3 Citas (Scopus)

Resumen

Purpose To compare rim area rates in patients with and without the visual field (VF) progression endpoint in the Canadian Glaucoma Study and determine whether intraocular pressure (IOP) reduction following the endpoint altered rim area rate. Design Prospective multicenter cohort study. Methods setting: University hospitals. patient population: Two hundred and six patients with open-angle glaucoma were examined at 4-month intervals with standard automated perimetry and confocal scanning laser tomography. intervention: After the endpoint, IOP was reduced by ≥20%. outcome measures: Univariate analysis for change in rim area rate and multivariable analysis to adjust for independent covariates (eg, age, sex, and IOP). Results Patients with an endpoint (n = 59) had a worse rim area rate prior to the endpoint compared to those without (n = 147; median [interquartile range]: -14 [-32, 11] × 10^-3 mm²/y and -5 [-14, 5] × 10^-3 mm²/y, respectively, P =.02). In univariate analysis, there was no difference in rim area rate before and after the endpoint (median difference [95% CI], 8 (-10, 24) × 10^-3 mm²/y), but the muItivariate analysis showed that IOP reduction >2 mm Hg after the endpoint was strongly linked to a reduction in rim area rate decline (8 × 10^-3 mm²/y for each additional 1 mm Hg reduction). Conclusions Patients with a VF endpoint had a median rim area rate that was nearly 3 times worse than those without an endpoint. Lower mean follow-up IOP was independently associated with a slower decline in rim area.

Idioma original	English
Páginas (desde-hasta)	140-147.e1
Publicación	American Journal of Ophthalmology
Volumen	163
DOI	https://doi.org/10.1016/j.ajo.2015.11.031
Estado	Published - mar. 1 2016

Nota bibliográfica

Funding Information:
Funding/Support: Funding was received from the following sources: The E. A. Baker Foundation of the Canadian National Institutes for the Blind, Toronto, Ontario, Canada; Glaucoma Research Society of Canada, Toronto, Ontario, Canada; unrestricted grants from Allergan Canada (Markham, Ontario, Canada), Merck Canada (Kirkland, Quebec, Canada), and Pfizer Canada (Kirkland, Quebec, Canada); National Institutes for Health Research, London, United Kingdom; and Special Trustees of Moorfields Eye Hospital (ST12 07E), London, United Kingdom. None of the funding bodies had a role in the design or conduct of study; any aspect of data collection, analysis or interpretation; or approval of the final manuscript. Financial disclosures: Mark R. Lesk: Aerie Pharmaceuticals, Bedminster, New Jersey, USA (research support, honoraria); Alcon Canada, Mississauga, Ontario, Canada; Allergan Canada, Markham, Ontario, Canada (lectures); Merck Canada, Kirkland, Quebec, Canada (lecture fees); Mimetogen Inc, Montreal, Quebec, Canada (consulting); Pfizer Canada, Kirkland, Quebec, Canada (research support). Marcelo T. Nicolela: Alcon Canada, Mississauga, Ontario, Canada (consulting, honoraria); Allergan Canada, Markham, Ontario, Canada (consulting, honoraria). Balwantray C. Chauhan: Allergan, Westport, Ireland (consulting, honoraria, lectures, speakers' bureau); Heidelberg Engineering, Heidelberg, Germany (research support, consulting). The following authors have no financial disclosures: Rizwan Malik, Neil O'Leary, Frederick S. Mikelberg, A. Gordon Balazsi, Raymond P. LeBlanc, and Graham E. Trope. All authors attest that they meet the current ICMJE criteria for authorship.

Publisher Copyright:
© 2016 Elsevier Inc. All rights reserved.

ASJC Scopus Subject Areas

Ophthalmology

PubMed: MeSH publication types

Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Acceder al documento

10.1016/j.ajo.2015.11.031

Otros archivos y enlaces

Citar esto

@article{e19fd203b8d44f299304b170bb23735c,

title = "Neuroretinal Rim Area Change in Glaucoma Patients with Visual Field Progression Endpoints and Intraocular Pressure Reduction. the Canadian Glaucoma Study: 4",

abstract = "Purpose To compare rim area rates in patients with and without the visual field (VF) progression endpoint in the Canadian Glaucoma Study and determine whether intraocular pressure (IOP) reduction following the endpoint altered rim area rate. Design Prospective multicenter cohort study. Methods setting: University hospitals. patient population: Two hundred and six patients with open-angle glaucoma were examined at 4-month intervals with standard automated perimetry and confocal scanning laser tomography. intervention: After the endpoint, IOP was reduced by ≥20%. outcome measures: Univariate analysis for change in rim area rate and multivariable analysis to adjust for independent covariates (eg, age, sex, and IOP). Results Patients with an endpoint (n = 59) had a worse rim area rate prior to the endpoint compared to those without (n = 147; median [interquartile range]: -14 [-32, 11] × 10-3 mm2/y and -5 [-14, 5] × 10-3 mm2/y, respectively, P =.02). In univariate analysis, there was no difference in rim area rate before and after the endpoint (median difference [95% CI], 8 (-10, 24) × 10-3 mm2/y), but the muItivariate analysis showed that IOP reduction >2 mm Hg after the endpoint was strongly linked to a reduction in rim area rate decline (8 × 10-3 mm2/y for each additional 1 mm Hg reduction). Conclusions Patients with a VF endpoint had a median rim area rate that was nearly 3 times worse than those without an endpoint. Lower mean follow-up IOP was independently associated with a slower decline in rim area.",

author = "{Canadian Glaucoma Study Group} and Rizwan Malik and Neil O'Leary and Mikelberg, {Frederick S.} and Balazsi, {A. Gordon} and Leblanc, {Raymond P.} and Lesk, {Mark R.} and Nicolela, {Marcelo T.} and Trope, {Graham E.} and Chauhan, {Balwantray C.} and Artes, {Paul H.} and Rafuse, {Paul E.} and Andrews, {David M.} and Mohammad Humayun and James Macneill and Orr, {Andrew C.} and Quigley, {John H.} and Sapp, {George A.} and Macdonald, {Christine A.} and Sauveur, {Helen M.} and Lavender, {Sara L.} and Kasner, {Oscar P.} and Saheb, {Nabil E.} and Coffey, {Alan J.} and Connolly, {W. Edward} and Discepola, {Marino J.} and Kavalec, {Conrad C.} and Lindley, {Susan K.} and Marc Mullie and Pearl Alexander and Bonnie May and Douglas, {Gordon R.} and Drance, {Stephen M.} and Blicker, {Jeffrey A.} and Cottle, {Robin S.} and Vincent Wong and Zarina Pardhan and Buys, {Yvonne M.} and Flanagan, {John G.} and Birt, {Catherine M.} and Easterbrook, {Michael W.} and Macrae, {William G.} and Markowitz, {Samuel N.} and Maureen Wolpert and Emad Eskander and Macgillivray, {Christine A.} and Erin Hicks and Kathryn Patterson and Andrew Vassallo and Pantelis Andreou",

note = "Funding Information: Funding/Support: Funding was received from the following sources: The E. A. Baker Foundation of the Canadian National Institutes for the Blind, Toronto, Ontario, Canada; Glaucoma Research Society of Canada, Toronto, Ontario, Canada; unrestricted grants from Allergan Canada (Markham, Ontario, Canada), Merck Canada (Kirkland, Quebec, Canada), and Pfizer Canada (Kirkland, Quebec, Canada); National Institutes for Health Research, London, United Kingdom; and Special Trustees of Moorfields Eye Hospital (ST12 07E), London, United Kingdom. None of the funding bodies had a role in the design or conduct of study; any aspect of data collection, analysis or interpretation; or approval of the final manuscript. Financial disclosures: Mark R. Lesk: Aerie Pharmaceuticals, Bedminster, New Jersey, USA (research support, honoraria); Alcon Canada, Mississauga, Ontario, Canada; Allergan Canada, Markham, Ontario, Canada (lectures); Merck Canada, Kirkland, Quebec, Canada (lecture fees); Mimetogen Inc, Montreal, Quebec, Canada (consulting); Pfizer Canada, Kirkland, Quebec, Canada (research support). Marcelo T. Nicolela: Alcon Canada, Mississauga, Ontario, Canada (consulting, honoraria); Allergan Canada, Markham, Ontario, Canada (consulting, honoraria). Balwantray C. Chauhan: Allergan, Westport, Ireland (consulting, honoraria, lectures, speakers' bureau); Heidelberg Engineering, Heidelberg, Germany (research support, consulting). The following authors have no financial disclosures: Rizwan Malik, Neil O'Leary, Frederick S. Mikelberg, A. Gordon Balazsi, Raymond P. LeBlanc, and Graham E. Trope. All authors attest that they meet the current ICMJE criteria for authorship. Publisher Copyright: {\textcopyright} 2016 Elsevier Inc. All rights reserved.",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.ajo.2015.11.031",

language = "English",

volume = "163",

pages = "140--147.e1",

journal = "American Journal of Ophthalmology",

issn = "0002-9394",

publisher = "Elsevier USA",

}

TY - JOUR

T1 - Neuroretinal Rim Area Change in Glaucoma Patients with Visual Field Progression Endpoints and Intraocular Pressure Reduction. the Canadian Glaucoma Study

T2 - 4

AU - Canadian Glaucoma Study Group

AU - Malik, Rizwan

AU - O'Leary, Neil

AU - Mikelberg, Frederick S.

AU - Balazsi, A. Gordon

AU - Leblanc, Raymond P.

AU - Lesk, Mark R.

AU - Nicolela, Marcelo T.

AU - Trope, Graham E.

AU - Chauhan, Balwantray C.

AU - Artes, Paul H.

AU - Rafuse, Paul E.

AU - Andrews, David M.

AU - Humayun, Mohammad

AU - Macneill, James

AU - Orr, Andrew C.

AU - Quigley, John H.

AU - Sapp, George A.

AU - Macdonald, Christine A.

AU - Sauveur, Helen M.

AU - Lavender, Sara L.

AU - Kasner, Oscar P.

AU - Saheb, Nabil E.

AU - Coffey, Alan J.

AU - Connolly, W. Edward

AU - Discepola, Marino J.

AU - Kavalec, Conrad C.

AU - Lindley, Susan K.

AU - Mullie, Marc

AU - Alexander, Pearl

AU - May, Bonnie

AU - Douglas, Gordon R.

AU - Drance, Stephen M.

AU - Blicker, Jeffrey A.

AU - Cottle, Robin S.

AU - Wong, Vincent

AU - Pardhan, Zarina

AU - Buys, Yvonne M.

AU - Flanagan, John G.

AU - Birt, Catherine M.

AU - Easterbrook, Michael W.

AU - Macrae, William G.

AU - Markowitz, Samuel N.

AU - Wolpert, Maureen

AU - Eskander, Emad

AU - Macgillivray, Christine A.

AU - Hicks, Erin

AU - Patterson, Kathryn

AU - Vassallo, Andrew

AU - Andreou, Pantelis

N1 - Funding Information: Funding/Support: Funding was received from the following sources: The E. A. Baker Foundation of the Canadian National Institutes for the Blind, Toronto, Ontario, Canada; Glaucoma Research Society of Canada, Toronto, Ontario, Canada; unrestricted grants from Allergan Canada (Markham, Ontario, Canada), Merck Canada (Kirkland, Quebec, Canada), and Pfizer Canada (Kirkland, Quebec, Canada); National Institutes for Health Research, London, United Kingdom; and Special Trustees of Moorfields Eye Hospital (ST12 07E), London, United Kingdom. None of the funding bodies had a role in the design or conduct of study; any aspect of data collection, analysis or interpretation; or approval of the final manuscript. Financial disclosures: Mark R. Lesk: Aerie Pharmaceuticals, Bedminster, New Jersey, USA (research support, honoraria); Alcon Canada, Mississauga, Ontario, Canada; Allergan Canada, Markham, Ontario, Canada (lectures); Merck Canada, Kirkland, Quebec, Canada (lecture fees); Mimetogen Inc, Montreal, Quebec, Canada (consulting); Pfizer Canada, Kirkland, Quebec, Canada (research support). Marcelo T. Nicolela: Alcon Canada, Mississauga, Ontario, Canada (consulting, honoraria); Allergan Canada, Markham, Ontario, Canada (consulting, honoraria). Balwantray C. Chauhan: Allergan, Westport, Ireland (consulting, honoraria, lectures, speakers' bureau); Heidelberg Engineering, Heidelberg, Germany (research support, consulting). The following authors have no financial disclosures: Rizwan Malik, Neil O'Leary, Frederick S. Mikelberg, A. Gordon Balazsi, Raymond P. LeBlanc, and Graham E. Trope. All authors attest that they meet the current ICMJE criteria for authorship. Publisher Copyright: © 2016 Elsevier Inc. All rights reserved.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose To compare rim area rates in patients with and without the visual field (VF) progression endpoint in the Canadian Glaucoma Study and determine whether intraocular pressure (IOP) reduction following the endpoint altered rim area rate. Design Prospective multicenter cohort study. Methods setting: University hospitals. patient population: Two hundred and six patients with open-angle glaucoma were examined at 4-month intervals with standard automated perimetry and confocal scanning laser tomography. intervention: After the endpoint, IOP was reduced by ≥20%. outcome measures: Univariate analysis for change in rim area rate and multivariable analysis to adjust for independent covariates (eg, age, sex, and IOP). Results Patients with an endpoint (n = 59) had a worse rim area rate prior to the endpoint compared to those without (n = 147; median [interquartile range]: -14 [-32, 11] × 10-3 mm2/y and -5 [-14, 5] × 10-3 mm2/y, respectively, P =.02). In univariate analysis, there was no difference in rim area rate before and after the endpoint (median difference [95% CI], 8 (-10, 24) × 10-3 mm2/y), but the muItivariate analysis showed that IOP reduction >2 mm Hg after the endpoint was strongly linked to a reduction in rim area rate decline (8 × 10-3 mm2/y for each additional 1 mm Hg reduction). Conclusions Patients with a VF endpoint had a median rim area rate that was nearly 3 times worse than those without an endpoint. Lower mean follow-up IOP was independently associated with a slower decline in rim area.

AB - Purpose To compare rim area rates in patients with and without the visual field (VF) progression endpoint in the Canadian Glaucoma Study and determine whether intraocular pressure (IOP) reduction following the endpoint altered rim area rate. Design Prospective multicenter cohort study. Methods setting: University hospitals. patient population: Two hundred and six patients with open-angle glaucoma were examined at 4-month intervals with standard automated perimetry and confocal scanning laser tomography. intervention: After the endpoint, IOP was reduced by ≥20%. outcome measures: Univariate analysis for change in rim area rate and multivariable analysis to adjust for independent covariates (eg, age, sex, and IOP). Results Patients with an endpoint (n = 59) had a worse rim area rate prior to the endpoint compared to those without (n = 147; median [interquartile range]: -14 [-32, 11] × 10-3 mm2/y and -5 [-14, 5] × 10-3 mm2/y, respectively, P =.02). In univariate analysis, there was no difference in rim area rate before and after the endpoint (median difference [95% CI], 8 (-10, 24) × 10-3 mm2/y), but the muItivariate analysis showed that IOP reduction >2 mm Hg after the endpoint was strongly linked to a reduction in rim area rate decline (8 × 10-3 mm2/y for each additional 1 mm Hg reduction). Conclusions Patients with a VF endpoint had a median rim area rate that was nearly 3 times worse than those without an endpoint. Lower mean follow-up IOP was independently associated with a slower decline in rim area.

UR - http://www.scopus.com/inward/record.url?scp=84959541490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959541490&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2015.11.031

DO - 10.1016/j.ajo.2015.11.031

M3 - Article

C2 - 26705093

AN - SCOPUS:84959541490

SN - 0002-9394

VL - 163

SP - 140-147.e1

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

ER -

Neuroretinal Rim Area Change in Glaucoma Patients with Visual Field Progression Endpoints and Intraocular Pressure Reduction. the Canadian Glaucoma Study: 4

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto